The Ministry of Food and Drug Safety must approve the import but a
government panel concluded remdesivir showed positive results, Korea
Centers for Disease Control and Prevention (KCDC) Director Jeong
Eun-kyeong said.
Foster City, California-based Gilead has said the drug has improved
outcomes for people suffering from the respiratory disease caused by
the novel coronavirus and has provided data suggesting it works
better when given in the early stages of infection.
Preliminary results from a trial led by the U.S. Institutes of
Health showed remdesivir cut hospital stays by 31% compared with a
placebo treatment, although it did not significantly improve
survival.
Remdesivir, which failed as a treatment for Ebola, is designed to
stop some viruses making copies of themselves inside infected cells.
After mounting a campaign of tracing and testing to blunt an initial
wave of coronavirus infections in February and March, South Korea
has seen smaller but persistent outbreaks as it has lifted some
social distancing restrictions in recent weeks.
[to top of second column] |
The latest spike in cases has been linked to a logistics facility near Seoul
operated by e-commerce giant Coupang.
The company is under scrutiny after health officials said some basic safety
measures were not followed as workers rushed to fulfil a huge increase in orders
driven by more online shopping.
As of midnight on Thursday, the KCDC reported 58 new cases, bringing the
country's total to 11,402, with 269 deaths.
Nearly 90 percent of new cases this week have been clustered in Seoul and
surrounding areas, raising concern that the densely populated capital could see
a wider outbreak.
Those concerns prompted officials to close most government-run facilities like
museums and galleries.
Education authorities, meanwhile, said they would press on with a phased
reopening of schools, but limited the number of children allowed in some.
Hundreds of schools across the country have been closed again as new cases
spring up.
(Reporting by Josh Smith and Hyonhee Shin; Editing by Robert Birsel)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |